<DOC>
	<DOCNO>NCT00834366</DOCNO>
	<brief_summary>To determine whether test product , Labopharm Tramadol HCl Once-A-Day ( OAD ) 200 mg film-coated tablet , reference product , Labopharm Tramadol HCl OAD 200 mg uncoated tablet , bioequivalent .</brief_summary>
	<brief_title>A Study Compare Relative Bioavailability Two 200 Mg Tramadol Hydrochloride Tablet Products Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Tramadol</mesh_term>
	<criteria>Healthy male female subject 18 55 year age ( inclusive ) . Body mass within 10 % ideal mass relation height age , accord Body Mass Index ( BMI ) . Body mass le 60 kg . Findings within range clinical acceptability medical history physical examination , laboratory result within `` normal range '' relevant laboratory test ( unless investigator consider deviation irrelevant purpose study ) . Normal electrocardiogram ( ECG ) vital sign , abnormality investigator consider disqualification participation study . Willingness undergo prestudy physical examination pre poststudy laboratory investigation . Ability comprehend willingness sign statement inform consent ( screen phaserelated procedure ) . Nonsmoker past smoker stop smoke least 3 month enter study . For female , follow condition meet : postmenopausal least 2 year , surgically sterilize , childbearing potential , follow condition meet : normal menstrual flow within 1 month study entry , negative serum pregnancy test screening . If test positive , subject exclude study receive study medication . In rare circumstance pregnancy discover subject receive study drug , every attempt must make follow subject term , must agree use accepted method contraception ( i.e. , spermicide barrier method spermicide Intrauterine Device ( IUD ) ) . The subject agree continue method throughout study . Hormonal contraceptives allow . Evidence psychiatric disorder , antagonistic personality , poor motivation , emotional intellectual problem likely limit validity consent participate study limit ability comply protocol requirement . History , current compulsive alcohol abuse ( &gt; 10 drink weekly ) , regular exposure substance abuse . Use medication , prescribed overthecounter , within 2 week prior first administration study medication except would affect outcome study opinion clinical investigator . Use hormonal contraceptive agent females allow . Participation another study experimental drug within 8 week first administration study medication . Treatment within previous 3 month drug welldefined potential adversely affect major organ system evidence effect . A major illness 3 month commencement screening period . History hypersensitivity study drug relate drug . History bronchial asthma . History epilepsy . Relevant history laboratory clinical finding indicative acute chronic disease , likely influence study outcome . Donation loss blood equal exceed 500 mL 8 week first administration study medication . Diagnosis hypotension make screening period . Diagnosis hypertension make screening period current diagnosis hypertension . Resting pulse &gt; 100 beat per minute &lt; 45 beat per minute screening period , either supine standing . Positive test hepatitis B antigen . Significant liver disease , define active hepatitis elevate liver enzymes ( e.g. , AST ( aspartate aminotransferase ) , Alanine transaminase ( ALT ) ) &gt; 2 time upper boundary normal range . Positive urine screen drug abuse . Positive urine screen tobacco use ( SureStepTM Smoke Check Tests OneStep Cotinine ( COT ) Tests ) . A serum pregnancy test ( betahCG ) either positive perform lactation . History marijuana , barbiturate , amphetamine narcotic abuse within 12 month prior study start . Participation tramadol study within previous 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Healthy volunteer</keyword>
</DOC>